Research Studies: Multiple System Atrophy

Currently Enrolling Studies

REDWOOD-0170 (MARIN/ Theravance) Assesing durability of effect of Study drug in patients with symptomatic orthostatic hypotension

• A phase 3, 22- week, Multi-center, Randomized Withdrawl Study of TD_9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure.

Upcoming Studies

MSA-101: Randomized, Double-Blind, Placebo-Controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy

• This study is testing a treatment called glial cell line-derived neurotrophic factor (GDNF) gene transfer to evaluate if it helps people with Multiple System Atrophy (MSA). During the procedure GDNF is delivered to a part of the brain called the putamen.

• The study will evaluate the safety and tolerability of the treatment and possible improvement in the clinical features of MSA.

• Expected to start enrolling: late Spring 2021